Canaccord Reiterates Buy on Cepheid (CPHD), Raises Target to $36
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD), raises PT from $30 to $36.
Canaccord analyst says, "We reiterate our rating on CPHD as it demonstrates the GeneXpert system continues to be the molecular instrument of choice with 120 systems placed in Q1. In addition, test revenue grew 24%. Given the premium valuation, we expect some investors to take a pass on shares of CPHD. However, we continue to expect GeneXpert to build on its 14% US penetration as the focus shifts to mid-volume hospitals, really leveraging CPHD’s strengths."
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $30.71 yesterday.
Canaccord analyst says, "We reiterate our rating on CPHD as it demonstrates the GeneXpert system continues to be the molecular instrument of choice with 120 systems placed in Q1. In addition, test revenue grew 24%. Given the premium valuation, we expect some investors to take a pass on shares of CPHD. However, we continue to expect GeneXpert to build on its 14% US penetration as the focus shifts to mid-volume hospitals, really leveraging CPHD’s strengths."
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $30.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
